01276.HK
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 46.50
+0.74%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +10.1%
- EBITDA
- +35.5%
- EPS
- +19.7%
Three-year CAGR
- Revenue
- +13.2%
- EBITDA
- +27.1%
- EBIT
- +28.8%
- Net income
- +24.5%
- EPS
- +24.1%
- Free cash flow
- +16.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026